Patient journey and decision processes for anti-amyloid therapy in Alzheimer’s disease
Only 5.3% of patients reached the point of care of being a candidate, scheduled for, or receiving AAT infusion. Patient preference and clinician discretion, especially regarding modifiable factors (e.g., medication regimens), appreciably influence the patient journey to AAT.
Authors
- K. Xia
- Stuart Clare
- Amir Abbas Tahami Monfared (ORCID: https://orcid.org/0000-0003-4003-3192)
- Karla Brandao-Viruet
- Peter J. Morin
- Joel I. Reisman (ORCID: https://orcid.org/0000-0002-0552-161X)
- Dan R. Berlowitz (ORCID: https://orcid.org/0000-0002-8783-5611)
- Ying Wang (ORCID: https://orcid.org/0000-0001-7808-6279)
- Weiming Xia (ORCID: https://orcid.org/0000-0002-7463-3295)
- Quanwu Zhang (ORCID: https://orcid.org/0000-0003-2442-939X)
- Donald R. Miller (ORCID: https://orcid.org/0000-0002-7881-8801)
- Michael C. Irizarry (ORCID: https://orcid.org/0000-0002-0246-2511)
- Brant S. Mittler
- Morgan Biskach
- Xavier Cambi
Institutions
- Boston University (US)
- Tufts Medical Center (US)
- University of Massachusetts Lowell (US)
- The University of Texas at San Antonio Health Science Center (US)
- Wentworth Institute of Technology (US)
- McGill University Health Centre (CA)
- Bedford VA Research Corporation (US)
- VA New England Healthcare System (US)
- Alzheimer’s Disease Neuroimaging Initiative (US)
- Quinnipiac University (US)
- McGill University (CA)
Publication Details
- Journal
- Journal of Neurology
- Published
- 2025-04-16
- DOI
- https://doi.org/10.1007/s00415-025-13059-3
- Citations
- 3
- Primary Topic
- Dementia and Cognitive Impairment Research
- Type
- article
- Field-Weighted Citation Impact
- 4.41
Funders
- U.S. Department of Veterans Affairs
- Office of Research and Development
- Health Services Research and Development
- Eisai
- National Institutes of Health
- Eisai Incorporated